Cite
Feasibility and efficacy of CD19-targeted CAR T cells with concurrent ibrutinib for CLL after ibrutinib failure
MLA
James Lymp, et al. “Feasibility and Efficacy of CD19-Targeted CAR T Cells with Concurrent Ibrutinib for CLL after Ibrutinib Failure.” Blood, vol. 135, no. 19, Aug. 2019. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....98b449c71ca830002004e4c2f1008159&authtype=sso&custid=ns315887.
APA
James Lymp, Barbara S. Pender, David G. Maloney, Cecilia C. S. Yeung, Rachel N. Steinmetz, Aesha Vakil, Alexandre V. Hirayama, Cameron J. Turtle, Stanley R. Riddell, Jordan Gauthier, Tinh-Doan Phi, Daniel H. Li, Reed M. Hawkins, Kevin A. Hay, Alyssa Sheih, Mazyar Shadman, & Janaki Purushe. (2019). Feasibility and efficacy of CD19-targeted CAR T cells with concurrent ibrutinib for CLL after ibrutinib failure. Blood, 135(19).
Chicago
James Lymp, Barbara S. Pender, David G. Maloney, Cecilia C. S. Yeung, Rachel N. Steinmetz, Aesha Vakil, Alexandre V. Hirayama, et al. 2019. “Feasibility and Efficacy of CD19-Targeted CAR T Cells with Concurrent Ibrutinib for CLL after Ibrutinib Failure.” Blood 135 (19). http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....98b449c71ca830002004e4c2f1008159&authtype=sso&custid=ns315887.